-
Mashup Score: 22
There is a need to understand and define disease modification in myelofibrosis. This review examines the latest clinical data of targeted therapies for myelofibrosis and proposes a definition of dise…
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 23Royals rookie Hill thriving after beating cancer - 5 day(s) ago
DETROIT — Royals rookie left-hander Tim Hill looked in the mirror and hardly recognized himself. A skeleton, he thought. He needed to take a photo, perhaps just to remind himself one day of this trying time in his life.It was the fall of 2015, and Hill was near completion of
Source: www.mlb.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Moving toward disease modification in polycythemia vera - 5 day(s) ago
Polycythemia vera is a BCR-ABL1–negative myeloproliferative neoplasm that reduces life expectancy through thrombosis, marrow failure, and transformation to leuk
Source: ashpublications.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Chernobyl and Biology: Dual Degree Prompts Alumni Award Winner to Pivot | School of Molecular & Cellular Biology | UIUC - 16 day(s) ago
Congratulations to Dr. Mesa, a 2024 College of Liberal Arts & Sciences Distinguished Alumni Award Recipient!
Source: mcb.illinois.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 13
CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 29Hope for a Rare Disease: Myelofibrosis - The Bloodline with LLS - 1 month(s) ago
“If you have a rare disease, it’s not rare to you.” In this episode, Dr. Naveen Pemmaraju of MD Anderson Cancer Center in Houston, TX, sheds light on the latest treatment advancements for myelofibrosis. The pace of scientific discovery for rare diseases is moving at a fast rate, resulting in better outcomes for myelofibrosis patients.
Source: thebloodline.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21) Selection of CD123-targeted therapy for patients with BPDCN (20:05) Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04) Future directions in the treatment of BPDCN (28:55)
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Featuring an interview with Prof Naveen Pemmaraju, including the following topics: Case: A woman in her mid 20s with classic blastic plasmacytoid dendritic cell neoplasm (BPDCN) who responded to combination hyper-CVAD/venetoclax (0:00) Defining and diagnosing BPDCN (5:17) Presentation, prevention and management of capillary leak syndrome (7:56) Targeting CD123 in BPDCN (12:53) Case: A man in his early 70s with TET-mutated BPDCN who had a complete response to tagraxofusp (14:21) Selection of CD123-targeted therapy for patients with BPDCN (20:05) Case: A man in his mid 60s who had a complete response to pivekimab sunirine (27:04) Future directions in the treatment of BPDCN (28:55)
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 57Amer Zeidan, MBBS, MHS, appointed inaugural Chief of the Division of Hematologic Malignancies - 2 month(s) ago
After an extensive national search, Amer Zeidan, MBBS, MHS, has been appointed inaugural Chief of the Division of Hematologic Malignancies at Yale Cancer Center
Source: medicine.yale.eduCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1Novel CD123-Targeting Antibody-Drug Conjugate in Relapsed or Refractory AML - The ASCO Post - 2 month(s) ago
In a phase I/II study reported in The Lancet Oncology, Naval Daver, MD, and colleagues found that pivekimab sunirine (IMGN632), a novel CD123-targeting antibody-drug conjugate, showed activity in patients with CD123-positive relapsed or refractory acute myeloid leukemia (AML). Ninety-one patients from nine sites in France, Italy, Spain, and the United States were enrolled in the first-in-human study between December 2017 and May 2020. The dose-escalation phase examined dose levels of pivekimab sunirine
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
#ASH23 | 👉👉👉Professor Passamonti & Professor Pemmaraju discussing all things #BCLXL & #DiseaseModification in #MPNSM together! @ASH_hematology || https://t.co/LMXAhxDpQq | @Barbara_MoraMD @Vikas_Gupta_1 @mpndoc @mpdrc @harrisoncn1 @jjkiladjian @AdamMead_Oxford https://t.co/r8iRjCN9vS